QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance

QIAGEN NV, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 38.80 as of March 27, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 15.36%, contrasting sharply with the S&P 500's gain of 11.87%. Despite its current challenges, QIAGEN maintains a market capitalization of USD 8,497 million and exhibits a price-to-earnings (P/E) ratio of 18.00. The company has demonstrated a strong ability to service its debt, evidenced by a low debt-to-EBITDA ratio of 0.91 times. However, its long-term growth prospects appear limited, with operating profit growing at an annual rate of just 5.15% over the last five years. In terms of financial health, QIAGEN reported an operating cash flow of USD 675.04 million, the highest recorded, and a return on capital employed (ROCE) of 10.81%. The stock is currently trading at a discount compared to its peers, despite a PEG ratio of 0.6, indicating a complex valuation landscape for investors.